Yesterday the NHS spending watchdog confirmed it would be rolled out to over 200,000 of the 3.4 million eligible Brits over ...
A new weight-loss jab will be rolled out on the NHS in England - but it could take 12 years for everyone to receive it, the ...
A study of two popular weight loss drugs, Zepbound and Wegovy, found that Zepbound was more effective helping people lose ...
Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables. Zepbound (tirzepatide), ...
New data indicating Eli Lilly’s obesity shot Zepbound works better than Novo Nordisk’s Wegovy could add fuel to Lilly’s new ...
People taking the weight loss drug Zepbound experienced dramatically greater weight loss than competitor Wegovy in the first head-to-head trial.
More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...
The randomized clinical trial showed that Zepbound patients achieved 47% more relative weight loss than Wegovy patients.
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.
Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical ...